Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02362217
Other study ID # PEACHI-04
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2014
Est. completion date October 31, 2017

Study information

Verified date October 2018
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers. The study also aims to assess the cellular immune response generated by these vaccines when administered as mentioned above.


Description:

Hepatitis C and HIV are both widespread pathogens. By the end of 2010, there were 2.3 million people in Europe living with HIV, over half of whom were coinfected with the Hepatitis C virus (HCV). Although vaccination is the optimal method of preventing infection, it has proved extremely difficult to develop an effective vaccine against HIV and HCV due to the enormous variation in strains around the world. This is caused by the extraordinary ability of the viruses to change their genetic material.

Researchers at the University of Oxford have developed novel candidate vaccines against HIV ('HIV.consv') and HCV ('NSmut'). These vaccines have been inserted into the carrier viruses Chimpanzee Adenovirus (ChAd or AdCh) and modified vaccinia virus Ankara (MVA), both of which have excellent safety records. The aim of this study is to test for the first time the response of the immune system when vaccines to both HIV and HCV are given together.

During this study, 32 healthy adults aged 18 to 50 years will be recruited into one of three groups to receive either two or four intramuscular injections over a period of two months. All participants will be followed up for a further six months (12 visits in total).


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date October 31, 2017
Est. primary completion date August 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy males or females, as assessed by medical history, physical examination and laboratory tests

- Aged at least 18 years on the day of screening and no greater than 50 years on the day of the first vaccination

- Resident in or easy access to the trial site for the duration of the study

- Available for follow-up for the planned duration of the study

- Able and willing (in the Chief Investigator's opinion) to comply with all study requirements

- Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner

- For females, willingness to practice continuous effective contraception from screening until 4 months after the last immunisation.

- All female volunteers must be willing to undergo urine pregnancy tests at the time points specified in the Schedule of Procedures and must have a negative pregnancy test on the day(s) of vaccination

- For sexually active men, willingness to use an approved method of contraception until four months after the last vaccination

- Agreement to refrain from blood donation during the course of the study

- In the opinion of the Chief Investigator or designee, the volunteer has understood the information provided. Written informed consent must be given before any study-related procedures are performed

- Willing to undergo HCV/HIV-1 testing, counselling and receive test results

Exclusion Criteria:

- Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period

- Prior receipt of a recombinant simian adenoviral vaccine

- Receipt of any investigational HIV-1 or HCV vaccine within the last 6 years

- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

- Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with the IMP

- Receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt within 14 days after vaccination with the IMP

- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressive medication within the past 6 months (inhaled and topical steroids are allowed)

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine

- History of clinically significant contact dermatitis

- Any history of anaphylaxis in reaction to vaccination

- Pregnancy, lactation or intention to become pregnant during the study

- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

- History of serious psychiatric condition

- Any other serious chronic illness requiring hospital specialist supervision

- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week

- Suspected or known injecting drug use

- Reported high-risk behaviour for HIV-1 / HCV infection

- Seropositive for hepatitis B surface antigen (HBsAg)

- Seropositive for HIV-1 (antibodies to HIV-1) at screening

- Seropositive for hepatitis C virus (antibodies to HCV) at screening

- Any other clinically significant acute or chronic medical condition that is considered unstable/progressive, or in the opinion of the Chief Investigator, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study

- Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis

- Any other finding which in the opinion of the investigators would significantly increase the risk of having an adverse outcome from participating in the protocol

- Vulnerable subjects (according to ICH GCP)

Study Design


Intervention

Biological:
AdCh3NSmut1
Genetic vaccine against Hepatitis C virus infection
MVA-NSmut
Genetic vaccine against Hepatitis C virus infection
ChAdV63.HIVconsv
Genetic vaccine against HIV-1 infection
MVA.HIVconsv
Genetic vaccine against HIV-1 infection

Locations

Country Name City State
United Kingdom Centre for Clinical Vaccinology and Tropical Medicine Oxford Oxfordshire

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford GlaxoSmithKline, ReiThera Srl

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of administering simultaneous HCV/HIV-1 prime-boost vaccinations, as measured by the proportion of volunteers who develop a grade 3 or 4 local or systemic reaction Proportion of volunteers who develop a grade 3 or 4 local reaction Proportion of volunteers who develop a grade 3 or 4 systemic reaction Actively collected throughout the study until 6 months after the last vaccination
Secondary Cellular immune response generated by simultaneous HCV/HIV-1 prime-boost vaccinations, as determined by analysing changes in the magnitude or quality of HCV and HIV-1-specific cellular immune responses. Immunogenicity determined by analysing changes from baseline in the magnitude or quality of HCV and HIV-1-specific cellular immune responses. These will be detected using several standardised assays. The primary outcome measure for immunogenicity will be the development of T cell responses to HCV and HIV-1 epitopes, as determined by IFN-? ELISpot assay. In addition, several exploratory immunology assays (including but not limited to intracellular cytokine staining, phenotype, viral suppression in vitro) will be developed and used. Actively collected throughout the study until 6 months after the last vaccination
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01680094 - Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Phase 1/Phase 2